Business ❯ Finance ❯ Investments

Pharmaceuticals

Eli Lilly Stock Market Clinical Trials Novo Nordisk Acquisitions Pfizer Drug Development Biotechnology Indian Pharma Stocks Stock Performance

Sanofi Expands Regeneron Collaboration to Develop Four New Antibody Therapies

The deal’s $1 billion upfront and up to $7 billion in milestones is meant to shore up Sanofi’s drug pipeline ahead of Dupixent patent challenges.

AstraZeneca Buys Stake in Summit to Pursue Cancer Drug Combinations

Lilly Pulls Ahead in GLP‑1 Market as Novo Confronts U.S. Headwinds

Nanexa Licenses PharmaShell to Novo Nordisk in Deal Worth Up to €1.17 Billion

Wall Street Lifts Eli Lilly After $1,600 Price Target Drives Rally

Amgen's Cash Strength Versus Moderna's mRNA Pivot

Novartis’ Del‑Desiran Misses Phase III and Triggers Large Share Selloff

Novartis' Pelacarsen Fails Phase 3 After Lowering Lp(a)

FDA Approves First Broad RAS Inhibitor for Metastatic Pancreatic Cancer

UK Approves Lilly’s Oral GLP‑1 Pill Foundayo

Novo Nordisk Sues Lilly Over Weight‑Loss Ads as GLP‑1 Rivalry Intensifies

Tenax Therapeutics Stock Collapses After Phase 3 Levosimendan Trial Misses Endpoints

Lilly Pulls Further Ahead in GLP-1 Race After Blowout Quarter

BioCryst Cuts Internal Discovery After Q2 ORLADEYO Gains and Pediatric Rollout

AstraZeneca and Bristol Myers Squibb Held Talks on $400 Billion Merger

Novo Nordisk’s Ziltivekimab Lowers Inflammation but Fails to Reduce Major Heart Events

Wall Street Unanimously Bullish on Teva as Austedo Fuels Turnaround

Eli Lilly's GLP‑1 Surge Leaves Pfizer as the High‑Yield Option

Eli Lilly Spends $3.8 Billion to Build Vaccine Business

Novo Nordisk Lifts 2026 Outlook as Wegovy Pill Powers Big Q1 Beat